Prevention of respiratory syncytial virus from 1991 to 2024: a systematic review and bibliometrics analysis.

IF 1.5 4区医学 Q2 PEDIATRICS Translational pediatrics Pub Date : 2024-10-01 Epub Date: 2024-10-28 DOI:10.21037/tp-24-271

Xue Li, Xia Yu, Zixi Du, Ling Zhang, Yeyuan Wang, Ying Wu, Yonghong Lin, Yulei He

{"title":"Prevention of respiratory syncytial virus from 1991 to 2024: a systematic review and bibliometrics analysis.","authors":"Xue Li, Xia Yu, Zixi Du, Ling Zhang, Yeyuan Wang, Ying Wu, Yonghong Lin, Yulei He","doi":"10.21037/tp-24-271","DOIUrl":null,"url":null,"abstract":"Background: Respiratory syncytial virus (RSV) puts children and elderly individuals worldwide at risk for severe health issues and financial difficulties. Prevention is the main treatment for RSV infection, as there is currently no particular therapy. By using bibliometrics analysis, this study attempted to map the increasing tendency in the prevention of RSV infection from January 1991 to August 2024 and to examine the frontiers and hotspots of related research.Methods: We extracted pertinent articles through the Web of Science Core Collection (WoSCC) on August 26, 2024, covering the period between January 1991 and August 2024. Then, an online bibliometrix interface (https://bibliometrics.com), R software (version 4.3.2), CiteSpace V6.1R6 (64-bit) software, and the Online Analysis Platform of Literature Metrology were used to analyze the data.Results: A total of 709 eligible data points pertaining to the prevention of RSV were included. The United States, England, and the Netherlands were the three major contributors to this field. The most productive journal was Vaccine. Centers for Disease Control and Prevention ranked first, with 22 publications in this field. The fusion (F) protein, nonstructural (NS) protein and glycoprotein (G) protein are the target proteins of RSV prevention drugs.Conclusions: In the past 30 years, the research on RSV prevention has entered a stage of rapid development, and many vaccines and monoclonal antibodies have entered the clinical research stage, and some have been marketed.","PeriodicalId":23294,"journal":{"name":"Translational pediatrics","volume":"13 10","pages":"1858-1869"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543136/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tp-24-271","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Respiratory syncytial virus (RSV) puts children and elderly individuals worldwide at risk for severe health issues and financial difficulties. Prevention is the main treatment for RSV infection, as there is currently no particular therapy. By using bibliometrics analysis, this study attempted to map the increasing tendency in the prevention of RSV infection from January 1991 to August 2024 and to examine the frontiers and hotspots of related research.

Methods: We extracted pertinent articles through the Web of Science Core Collection (WoSCC) on August 26, 2024, covering the period between January 1991 and August 2024. Then, an online bibliometrix interface (https://bibliometrics.com), R software (version 4.3.2), CiteSpace V6.1R6 (64-bit) software, and the Online Analysis Platform of Literature Metrology were used to analyze the data.

Results: A total of 709 eligible data points pertaining to the prevention of RSV were included. The United States, England, and the Netherlands were the three major contributors to this field. The most productive journal was Vaccine. Centers for Disease Control and Prevention ranked first, with 22 publications in this field. The fusion (F) protein, nonstructural (NS) protein and glycoprotein (G) protein are the target proteins of RSV prevention drugs.

Conclusions: In the past 30 years, the research on RSV prevention has entered a stage of rapid development, and many vaccines and monoclonal antibodies have entered the clinical research stage, and some have been marketed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

1991 至 2024 年呼吸道合胞病毒的预防：系统综述和文献计量学分析。

背景：呼吸道合胞病毒（RSV）使全球儿童和老年人面临严重健康问题和经济困难的风险。预防是治疗 RSV 感染的主要方法，因为目前还没有特别的疗法。通过文献计量学分析，本研究试图描绘 1991 年 1 月至 2024 年 8 月期间预防 RSV 感染的增长趋势，并考察相关研究的前沿和热点：我们于 2024 年 8 月 26 日通过科学网核心文献库（WoSCC）提取了相关文章，时间跨度为 1991 年 1 月至 2024 年 8 月。然后使用在线文献计量学界面（https://bibliometrics.com）、R软件（4.3.2版）、CiteSpace V6.1R6（64位）软件和文献计量学在线分析平台对数据进行分析：结果：共纳入了 709 个与预防 RSV 有关的符合条件的数据点。美国、英国和荷兰是这一领域的三大主要贡献者。产量最高的期刊是《疫苗》。美国疾病控制和预防中心排名第一，在该领域发表了 22 篇论文。融合蛋白（F）、非结构蛋白（NS）和糖蛋白（G）是 RSV 预防药物的靶蛋白：近 30 年来，RSV 预防研究进入快速发展阶段，许多疫苗和单克隆抗体已进入临床研究阶段，部分已上市。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊